Search Results (1,158)

Multiple myeloma (MM) is a blood cancer characterized by the accumulation of abnormal plasma cells within the bone marrow (BM). The neoplastic expansion progressively disrupts normal blood cell production by outcompeting healthy hematopoietic cells. The disease is characterized by terminally differentiated B cells that secrete antibodies as part of an adaptive immune response. A serious threat confronting small drug molecule therapy for MM is the lack of selective drug targeting, ultimately resulting in insufficient accumulation of drugs to target cells, and harmful off-target drug effects. We now report on the use of cellular lipid extracts (LEs) originating from two different human multiple myeloma (target) cell lines, RPMI 8226 and NCI H929, to develop RPMI 8226 LE- and NCI H929 LE-modified nanoliposomes, respectively. Other ingredients included phospholipid DOPC (dioleoyl-phosphatidylcholine) and/or Chol (cholesterol). Additional cell lines included non-target (Y79-retinoblastoma, U937-lymphoma, K562-GFP-chronic myeloid leukemia) and (off-target) normal healthy PBMCs—peripheral blood mononuclear cells. The LE-modified nanoliposomes stably incorporated various cytotoxic agents, demonstrating novel formulation characteristics and cell-interaction profiles. RPMI 8226 LE enhanced nanoliposome targeting to source-originating RPMI 8226 cells, with diminished uptake by Y79 and PBMCs. The inclusion of Chol reduced targeting to RPMI 8226 cells. The RPMI 8226 LE enhanced nano-formulation effects against RPMI 8226 cells, but not against the Y79 control. Consistent with these findings, RPMI 8226 LE-modified nano-formulations enhanced extracellular lactate dehydrogenase release against RPMI 8226 cells, but not against the Y79 control. NCI H929 LE material also enhanced targeting and nano-formulation effects against source and non-originating source tumor cells from the BM. Designing nanoliposomes to mimic tumor cell membranes may represent a powerful strategy to treat multiple myeloma. Significance: Cellular membrane lipid extracts derived from multiple myeloma cells enhanced targeting and cytotoxicity while limiting damage to normal healthy cells. The inclusion of LE materials in drug delivery systems may represent a promising strategy to enhance cellular targeting and drug therapy for multiple myeloma. Full article

Background: Polydatin has shown anti-inflammatory, antioxidant, and cytoprotective effects in preclinical studies. Its development is limited by low oral bioavailability, extensive metabolism, and poorly defined tissue exposure. Objectives: This review summarizes the pharmacology and delivery systems of polydatin, distinguishes nano from non-nano formulations, and examines the evidence for improved exposure, tissue delivery, safety, and clinical translation. Methods: Relevant studies were identified through a structured PubMed search and assessed by formulation type, administration route, comparator, and reported endpoints. Results: Delivery strategies include liposomes, polymeric and polysaccharide nanoparticles, lipid-based formulations, inclusion complexes, solid-state systems, hydrogels, local matrices, and targeted systems. Only a few oral formulations have been compared directly with free polydatin using quantitative pharmacokinetic measurements. Many injectable and local studies report release, cellular uptake, fluorescence distribution, or pharmacodynamic effects, but these findings do not by themselves demonstrate improved bioavailability or drug-specific targeting. Evidence on repeat-dose toxicity, immunogenicity, carrier clearance, and manufacturing consistency remains limited. No clinical study of a polydatin nanocarrier was identified. Conclusions: Further development requires appropriate free-polydatin controls, measurement of polydatin and its metabolites, exposure–response analysis, fuller safety assessment, and reproducible product characterization. Full article

Oral nanocarrier development for inflammatory bowel disease (IBD) is complicated by inflammation-dependent changes in mucus, epithelial integrity, and immune-cell interactions. This critical narrative review examines comparative evidence from in vitro systems, animal models, and human intestinal tissue, alongside clinical studies, to assess how barrier state modifies formulation performance. Across the reviewed studies, particle size alone does not consistently predict lesion accumulation, while surface chemistry, coating, geometry, and stability in gastrointestinal fluids influence mucus interaction, cellular access, and payload release. Tissue-associated fluorescence, increased permeability, and cellular uptake do not independently establish intact-carrier transport or productive delivery. Clinical trials of selected oral nano-enabled formulations report improvements in some disease outcomes but do not establish inflammation-selective delivery as the underlying mechanism. We propose an evidence-informed benchmarking framework linking characterization in biological media to mucus transport or retention, epithelial–immune responses, spatial localization, target engagement, and safety. Matched healthy and inflamed comparators are central to testing selectivity, and preclinical findings must be distinguished from clinical validation. Artificial intelligence may support barrier-state-aware formulation optimization but requires standardized datasets and prospective experimental validation. Given the heterogeneous evidence base and limited direct human delivery studies, prospective validation should prioritize local payload delivery and therapeutic benefit without exacerbating intestinal barrier injury. Full article

Background: Stigmasterol (St) holds promise as a natural cholesterol-lowering agent, yet its poor aqueous solubility and low bioaccessibility severely constrain its application in functional foods. Methods: In this study, we exploited whey protein peptides (WPP) with intrinsic cholesterol esterase (CEase) inhibitory activity to construct St-loaded self-assembled nanoparticles. Subsequently, we investigated its physicochemical properties and formation mechanism and evaluated its hypocholesterolemic activity through animal experiments. Results: Driven by non-covalent hydrophobic and hydrogen-bonding interactions, the optimized St-loaded WPP nanoparticles (St@WPP) ((234.47 ± 1.36) nm) achieved a high encapsulation efficiency (EE) of 74.73% ± 2.19%. This nano-encapsulation markedly improved St dispersibility and storage stability, and significantly elevated its bioaccessibility from 9.00% ± 0.14% to 19.41% ± 0.69% after simulated gastrointestinal digestion. St@WPP administration effectively ameliorated dyslipidemia, as evidenced by reduced serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), which may be associated with reduced intestinal cholesterol availability and increased fecal cholesterol content. Moreover, St@WPP alleviated hepatic steatosis, attenuated systemic inflammation, and rebalanced gut microbiota architecture. Conclusions: Collectively, the WPP shell functions as a delivery carrier that improves the water solubility and bioaccessibility of St, thereby broadening its potential for application in low-fat or aqueous-based food systems. The resulting St@WPP exhibits notable cholesterol-lowering activity, positioning it as a promising functional food ingredient with potential benefits for cholesterol management. Full article

Cancer remains a major global health challenge, and the limitations of conventional therapies, including systemic toxicity, drug resistance, and poor tumor selectivity, continue to drive the development of advanced nanomedicine strategies. In this context, nanocarriers offer promising opportunities to improve pharmacokinetics, enhance tumor accumulation, and enable controlled or stimuli-responsive drug release. Among them, inorganic nanoparticles (NPs) have gained considerable attention because of their structural stability, tunable surface chemistry, and multifunctional capabilities. Their performance depends on a structure–property–function relationship in which composition, morphology, porosity, degradability, and surface characteristics strongly influence interactions at the nano–bio interface. This review examines the main classes of nanoplatforms currently explored for cancer therapy, including inorganic, polymeric, lipid-based, and hybrid organic–inorganic systems. Particular attention is given to the trade-offs that define each platform in terms of loading capacity, biodegradability, multifunctionality, and translational potential. The discussion also highlights the role of predictive biological models, emphasizing that 3D spheroids, organoids, and organ-on-chip systems provide more realistic insights than conventional 2D assays for evaluating tumor penetration and microenvironment-responsive delivery. In addition, the review considers emerging directions in AI-guided nanoparticle engineerization design and natural-compound-based nanomedicines, both of which are expanding the therapeutic landscape. Overall, the field is moving toward more integrated, application-specific, and clinically translatable nanomedicine platforms capable of addressing the complex biological barriers of cancer treatment. Full article

Type 2 diabetes mellitus (T2DM) remains a global health crisis, with nearly 589 million adults currently affected and projections pointing toward 853 million by 2050. Despite an expanding pharmacological armamentarium, a significant proportion of patients fail to achieve adequate glycaemic control, and the limitations of existing therapies, including adverse effects, cost, and limited accessibility, underscore the compelling need for novel therapeutic approaches. Phytochemicals such as curcumin, berberine, quercetin, resveratrol, and epigallocatechin gallate possess well-documented antidiabetic activity, operating through the PI3K/Akt, AMPK (activated protein kinase), NF-κB/JNK (nuclear factor kappa-B), and GLP-1R (glucagon-like peptide-1) signalling axes to improve insulin sensitivity, suppress gluconeogenesis, protect pancreatic beta-cells, and attenuate chronic metabolic inflammation. However, their clinical utility has been fundamentally constrained by poor oral bioavailability arising from low aqueous solubility, gastrointestinal instability, extensive first-pass metabolism, and P-glycoprotein-mediated efflux. Advanced drug delivery systems, including liposomes, solid lipid nanoparticles (SLN), nanostructured lipid carriers, PLGA (Poly (lactic-co-glycolic acid)) and chitosan nanoparticles, nanoemulsions, self-nanoemulsifying drug delivery systems, and phytosomes have demonstrated the capacity to overcome these barriers, achieving five- to ten-fold improvements in systemic bioavailability and substantially enhanced antidiabetic efficacy in preclinical models. Emerging mechanistic evidence further positions gut microbiota modulation and epigenetic reprogramming as additional therapeutic axes through which nano-encapsulated phytochemicals may exert durable metabolic benefits. Nonetheless, critical translational challenges persist, encompassing nanotoxicological risks, herb–drug interactions, the absence of harmonised regulatory frameworks for nano-phytomedicine products, phytochemical raw material variability, and formidable technical and economic barriers to scalable nanoparticle manufacturing. This review synthesises the current mechanistic, formulation, and clinical evidence within a unified analytical framework and identifies the strategic priorities of rigorous clinical development, regulatory clarity, and manufacturing standardisation required to translate nano-phytomedicine science into evidence-based T2DM therapeutics. Full article

Mangrove ecosystems represent critical coastal blue carbon sinks, whose ecological stability is essential for sustaining carbon sequestration capacity and coastal ecological security. Hyblaea puera, a dominant defoliating pest in mangrove habitats, exhibits abrupt population outbreaks and extreme destructive potential, severely threatening the integrity of blue carbon ecosystems. While conventional broad-spectrum chemical insecticides deliver adequate control efficacy, they often exert detrimental effects on non-target organisms and adjacent coastal marine environments, conflicting with core mangrove conservation objectives. Azadirachtin, a botanical insecticide with high lepidopteran target highly selective, is a promising eco-friendly alternative; nevertheless, the dual stresses of periodic tidal flushing and intense ultraviolet radiation in intertidal mangrove habitats drive rapid photodegradation and leaching loss of azadirachtin, leading to poor field persistence and slow lethal action of the free formulation. These limitations render neat azadirachtin insufficient to meet the urgent demand for rapid emergency control of H. puera during population outbreaks. To address these technical bottlenecks, we developed an azadirachtin-loaded dendritic mesoporous silica nanoparticle delivery system to simultaneously improve the environmental stability and fast-acting insecticidal efficacy of azadirachtin against H. puera. Specifically, dendritic mesoporous silica nanoparticles (DMSNs) were synthesized via a one-pot method, then loaded with azadirachtin (ADT) and further surface-modified with polyether-modified heptamethyltrisiloxane (PM) to fabricate the ADT@DMSN/PM nano-delivery system. The physicochemical properties, intertidal habitat adaptability, insecticidal activity, and environmental safety of the fabricated system were systematically evaluated. Characterization results showed that the as-synthesized DMSNs had a uniform particle size of 200–300 nm, a specific surface area of 260.99 m²/g, and an ADT loading efficiency of 66.6%. ADT@DMSNs exhibited prominent alkaline-responsive sustained-release behavior, with a cumulative ADT release of 57.0% at pH 8.2 (mangrove seawater conditions) over 500 h. Laboratory bioassays revealed that the 24 h median lethal concentrations (LC₅₀) of ADT@DMSNs against third-, fourth-, and fifth-instar H. puera larvae were 84.36, 188.08, and 458.65 μg/mL, respectively, representing 2.38-, 2.63-, and 2.86-fold enhancements in insecticidal activity compared with free ADT. After modification with the PM adjuvant, the nanoformulation exhibited a significantly reduced contact angle on Avicennia marina leaves, over 3-fold higher foliar penetration efficiency, and markedly improved tidal wash-off resistance. Field cage bioassays demonstrate that the ADT@DMSN/PM nanoformulation yields a corrected mortality of approximately 95% against H. puera larvae at 1200 mg/L at 24 h. This nano-delivery system is precisely tailored to the unique environmental constraints of mangrove intertidal habitats, offering a novel eco-friendly technical approach to achieve rapid emergency control of H. puera outbreaks. Full article

Aberrant cell-surface sialylation is widely associated with cancer progression and provides an accessible molecular feature for biosensing and targeted delivery. However, engineering molecularly imprinted polymer nanoparticles (nanoMIPs) that combine selective sialic acid (SA) recognition with controlled degradability and cytocompatibility remains challenging. In this study, a simulation-guided strategy was used to develop hydrolytically degradable SA-imprinted nanoMIPs incorporating a functionalized lactose-based crosslinker with cleavable ester linkages. Molecular docking and quantum-chemical calculations identified N-isopropylacrylamide (NIPAM), acrylamide (AAm), and N-hydroxyethyl acrylamide (HEAA) as complementary functional monomers and established an optimized SA:NIPAM:AAm:HEAA molar ratio of 1:1:2:1. The resulting nanoMIPs were spherical and nanoscale and exhibited pH-dependent hydrolytic mass loss that was more pronounced under mildly acidic conditions than at physiological pH. Compared with non-imprinted nanoparticles, the nanoMIPs displayed substantially enhanced SA binding, with a maximum binding capacity of 89.38 μmol g⁻¹ and an imprinting factor of approximately 4.2, together with preferential recognition of SA over the selected competing molecules. MTT assays using MCF-7, HeLa, and HaCaT cells showed cell viability above 80% after 24 h exposure to 500 μg mL⁻¹, indicating favorable short-term cytocompatibility. By integrating computationally optimized, multicomponent SA recognition with a carbohydrate-derived, hydrolytically degradable crosslinking strategy, this work addresses the coupled requirements of binding-site fidelity and material degradability within a single nanoMIP platform. These findings establish a materials-level foundation for future SA-directed biosensing and targeted delivery systems in cancer-relevant applications. Full article

Background/Objectives: Electrospun polyvinylpyrrolidone (PVP) fibers are highly promising for fast-dissolving drug delivery. Methods: In this study, five PVP grades with molecular weights ranging from 4000 to 1,300,000 Da were investigated over a broad concentration range (10–60 w/w%) to evaluate their electrospinnability and dissolution behavior. Results: A well-defined viscosity window of approximately 150–680 mPa·s was identified for the formation of continuous, bead-free fibers. Deviations from this optimal window resulted in electrospraying or jet instability. Continuous fibers were successfully prepared from all investigated PVP grades, including low-molecular-weight PVP K-12 (Mw 4000), demonstrating that appropriate solution viscoelasticity can compensate for limited chain entanglement. Remarkably, in vitro testing revealed that all fibrous formulations exhibited ultrafast disintegration (0.29–1.33 s) and dissolution (0.39–2.32 s). Statistical analysis confirmed no significant differences attributable to polymer molecular weight or fiber diameter, effectively challenging the common assumption that higher-molecular-weight PVP delays disintegration. Instead, the immediate dissolution originates from rapid wetting and capillary-driven fluid uptake, facilitated by the highly porous nano- and microfibrous network. Conclusions: By highlighting the dominant role of macroscopic structural properties over polymer chain length, these findings provide a practical framework for the development of fast-dissolving electrospun PVP-based drug delivery systems. Full article

Biochar has traditionally been investigated as a soil amendment for improving fertility, carbon sequestration, and nutrient retention. However, recent advances in fine milling, colloidal stabilization, and nanotechnology have enabled the development of biochar-derived materials for foliar application. Unlike conventional soil application, foliar delivery enables direct interaction with leaf tissues, potentially providing faster physiological responses, improved resource-use efficiency, and complementary functions to existing plant biostimulants. This review critically evaluates the scientific basis, agronomic performance, and regulatory implications of foliar biochar applications across diverse crop systems. We synthesize and compare major formulation types, including finely milled suspensions, aqueous extracts, nano-biochar dispersions, and biochar-based composite carriers, based on their formulation characteristics, application methods, and reported biological effects. Across multiple crops, foliar biochar has been associated with enhanced chlorophyll content, improved gas exchange, strengthened antioxidant systems, better osmotic adjustment, and increased nutrient uptake, particularly under abiotic stresses such as salinity, drought, and heat. Mechanistically, these responses are linked to surface deposition effects, redox-active functional groups, modulation of leaf microclimate, and delivery of soluble bioactive compounds. Nevertheless, outcomes remain highly context-dependent, influenced by feedstock origin, pyrolysis conditions, particle size, formulation chemistry, dose, and crop species. Potential risks including phytotoxicity, nanoparticle exposure, environmental fate, and regulatory ambiguity especially for nano-scale formulations pose additional challenges for large-scale adoption. By integrating physiological, agronomic, environmental, and legislative perspectives, this review also highlights key barriers to commercialization, including formulation stability, limited field-scale validation, environmental safety, and regulatory uncertainty, while identifying research priorities needed to determine whether foliar biochar can become a scalable and scientifically validated biostimulant for sustainable agriculture. Full article

Gene delivery with cationic polymers requires balancing DNA compaction, colloidal stability, and intracellular release, yet for imine-linked low-molecular-weight polyethyleneimine (PEI) vectors, quantitative relationships connecting the N/P ratio with the full property–transfection cascade remain undefined. Here, two amphiphilic non-viral vectors were prepared by linking a hydrophobic benzene–siloxane core (TAS) to hyperbranched PEI (800 or 2000 Da) through reversible imine bonds and complexed with DNA across a broad N/P range (10–600). Polyplexes were characterized by atomic force microscopy (AFM), dynamic light scattering (DLS), ζ-potential, agarose gel electrophoresis, transfection via green fluorescent protein (GFP) imaging and luciferase assay in HeLa cells. Both vectors formed spherical nano-entities (AFM diameters ~30 nm for TAS-PEI800; ~100 nm for TAS-PEI2000). TAS-PEI2000 achieved complete DNA retardation at N/P ≈ 30 versus N/P ≈ 150 for TAS-PEI800, consistent with its higher charge density (ζ = +37.59 vs. +18.35 mV). Transfection efficiency was superior for TAS-PEI2000 across most N/P ratios; however, TAS-PEI2000 displayed an optimal transfection efficiency at N/P ≈ 100 (ζ ≈ 3.84 mV), beyond which efficiency declined, indicating a binding–release trade-off. Cell viability remained >77% across the N/P range for TAS-PEI800, but dropped below 25% at N/P ≥ 400 for TAS-PEI2000. A phenomenological logistic model identified characteristic transition thresholds (θ ≈ 60 for TAS-PEI800; θ ≈ 40 for TAS-PEI2000), capturing the onset of cooperative self-assembly; however, the post-optimum decline observed for TAS-PEI2000 requires additional inhibitory terms. These findings demonstrate that PEI molecular weight governs both the N/P threshold required for efficient transfection and the width of the therapeutic window, thereby providing structure–activity descriptors for the rational design of imine-linked polyplex systems. Full article

Melanin nanoparticles (MNPs) have attracted growing attention in biomedical fields due to their wide bioavailability, high biocompatibility, biodegradability, and multifunctionality. Key features of MNPs are broad-spectrum light absorption, high drug-loading capacity, near-infrared light-triggered drug release and reactive oxygen species generation, efficient hepatobiliary, renal clearance, and superior binding affinity towards metal ions that enhance MNPs’ traceability in magnetic resonance imaging (MRI). Despite challenges such as agglomeration in time, lack of extraction standardization, and a limited number of animal and clinical studies, the strong photothermal conversion and reactive species production abilities of MNPs make them effective photosensitizers and photothermal agents, while their dual capability for molecular binding and metal chelation positions them as promising agents for theranostic applications. This review provides a comprehensive overview of MNPs, covering their structural features, manufacturing methods and associated limitations, and recent advances in their physicochemical characterization. Special focus is given to MRI-guided biomedical applications, including drug delivery, photothermal therapy, and photodynamic therapy, along with critical challenges related to the clinical translation and commercialization of MNP-based platforms. By consolidating recent advances, this review highlights key structure–function relationships that underpin emerging melanin-based nano-systems. Full article

Background/Objectives: Nanotechnology has become a transformative area in modern dentistry, providing new opportunities for better diagnosis, targeted drug delivery, improved restorative materials, antimicrobial treatments, and tissue regeneration. This scoping review outlines the scope, key developments, and future directions of nanotechnology use across all dental specialties, highlights emerging innovations, and identifies major translational challenges and research priorities. Methods: This review followed the Joanna Briggs Institute (JBI) methodology for scoping reviews and adhered to the PRISMA-ScR guidelines. These guidelines, originally by Arksey and O’Malley (2005) and later updated by Levac et al. (2010) and Peters et al. (2020, 2021), guided the process. The Population, Concept, and Context (PCC) framework guided the eligibility criteria. Included studies were primary research or reviews reporting nanotechnology applications in any dental specialty, published in English, with no date restriction. Excluded were non-peer-reviewed sources, conference abstracts without full text, studies unrelated to dental applications, and non-English publications. A comprehensive literature search was conducted across PubMed/MEDLINE, Scopus, and Web of Science. After screening titles and abstracts and reviewing full texts, 133 studies were included. Results: The included studies covered a wide range of fields such as restorative dentistry, implantology, periodontology, endodontics, drug delivery, tissue regeneration, oral diagnostics, antimicrobial applications, prosthodontics, orthodontics, and emerging technologies like nanorobotics and graphene-based systems. The most commonly reported nanomaterials were silver nanoparticles (AgNPs), calcium phosphate nanoparticles (CaP NPs), and polymeric nanoparticles such as PLGA and chitosan. Additionally, there was a notable increase in publications starting from 2019. Conclusions: Nanotechnology offers transformative possibilities in every area of dentistry. Nonetheless, challenges such as nanotoxicology safety, regulatory alignment, and effective clinical application need resolution. Essential steps include standardized characterization, gathering long-term safety data, and establishing international regulatory standards to ensure safe adoption of nano dentistry. Full article

Plant anthracnose, caused by Colletotrichum spp., is a class of significant diseases that severely threatens global crop production. Traditional management strategies, including chemical control, are hindered by inherent limitations such as the frequent emergence of pathogen resistance, low pesticide utilization efficiency, high environmental residue risks, and inconsistent field efficacy. Moreover, achieving further improvements in control efficacy is constrained by the complex biological characteristics of Colletotrichum species, particularly their hemibiotrophic lifestyle and latent infection strategies. In recent years, nanotechnology has emerged as a potential approach for the management of anthracnose. This review summarizes the research progress of various nanomaterials in the control of plant anthracnose. It analyzes the proposed multi-mechanism modes of action of nanomaterials tailored to the specific infection traits of Colletotrichum. Particular emphasis is placed on analyzing the theoretical mechanisms and preliminary in vitro evidence of nano-enabled controlled-release systems in addressing asymptomatic latent infections and achieving targeted, precise delivery. However, it must be emphasized that most current findings are derived from laboratory or controlled-environment studies, and the actual field-scale effectiveness, long-term environmental behavior, and multi-trophic safety of many nanomaterials remain insufficiently confirmed. Building upon these insights, this review thoroughly evaluates the critical challenges facing the agricultural field application of nanomaterials, such as ecotoxicity, formulation stability, scalable industrial production, and regulatory gaps. This review aims to provide objective theoretical support and technical references for achieving safe, efficient, and sustainable nano-enabled green management of plant anthracnose. Full article

Periodontitis and dental caries remain among the most prevalent chronic diseases, and their local treatment is limited less by the choice of active agent than by the difficulty of sustaining therapeutic concentrations against salivary and crevicular clearance, the mucosal barrier and the biofilm matrix. This narrative review (PubMed/MEDLINE, Scopus, Web of Science; 2010–2026; 118 sources) maps five mechanistic classes—mucoadhesive, in situ gelling, stimuli-responsive, nano-/microparticulate and biomimetic—alongside marketed sustained-release products onto the specific barrier each addresses and onto an explicit translational gradient. The barriers are quantified rather than described: a pocket of ≈0.5 µL perfused at ≈20 µL/h turns over some 40 times hourly, giving an intra-crevicular half-life of about one minute, and the inflamed pocket is neutral-to-alkaline (pH 7.4–8.5), so acid-triggered release is a cariogenic and not a periodontal strategy, whereas alkaline-triggered release remains an open design space. A dose calculation from these figures identifies payload potency and deliverable mass, not carrier retention, as the binding constraint on phytocompound delivery. Because no single class overcomes all barriers, hybrid nano-in-macro architectures are analysed as the structural solution. Measured against a marketed benchmark of ≈0.3 mm additional probing-depth reduction, progress now depends on consolidation rather than on novelty. Full article